Point32Health has nearly 2 million members, while Blue Cross has 3 million in Massachusetts
GLP-1 Receptor Activation This is the same pathway used by Semaglutide (Ozempic, Wegovy): Suppresses appetite via hypothalamic signaling Delays gastric emptying , prolonging fullness Improves insulin secretion and glucose control Lowers postprandial glucose and insulin resistance GIP Receptor Activation Shared with Tirzepatide, GIP provides several synergistic effects: Enhances insulin release in response to meals May reduce GI side effects (like nausea) seen with GLP-1s alone Potentially improves lipid metabolism and adipose tissue response Glucagon Receptor Activation This is where Retatrutide takes a leap beyond dual agonists: Increases energy expenditure and fat oxidation Mobilizes stored fat through hepatic lipolysis May preserve or enhance lean mass during weight loss Supports brown fat activation and thermogenesis The addition of glucagon receptor activation to GLP-1 and GIP may enhance fat oxidation and energy burn beyond whats seen with dual agonists. Coskun et al., Cell Metabolism Together, these pathways work synergistically: GLP-1 blunts hunger , GIP improves insulin dynamics , and glucagon turns up fat-burning efficiency
GLP-1 innovation vector (5): Cost and coverage As noted above, employers and payers are increasingly grappling with how much GLP-1 coverage they can sustain
Sarika Arora, MD Ozempic and Wegovy are the leading brand names among a class of weight loss drugs known as GLP-1 receptor agonists (GLP-1 RAs)
Many patients use these drugs for weight management rather than diabetes, and these medications may not be captured in routine medication reconciliation if patients do not volunteer the information
As top-rated ophthalmologists serving patients across London, Chelmsford, and Hatfield, Blue Fin Vision provides expert guidance on these emerging concerns
